Skip to content
CancerIndex

Publication

Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.

Authors not recorded

Ann Oncol2020PMID 32348852PMC7396305stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
32348852
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
NTRK1 Fusion1
(oncogenic)Malignant Breast NeoplasmOncogenicCSupports Oncogenicity2accepted
EID10897

Of the 4854 Breast Cancer patients analyzed by Memorial Sloan Kettering-IMPACT targeted DNA sequencing and MSK-Fusion targeted RNA-seq, fusions were detected in 27 patients. One of these patients was … (full text at CIViC)

PMID 32348852 · Ross et al., 2020 · Open in CIViC

civic